Dendroid Peptide Structural Mimetics of ω-Conotoxin MVIIA based on a 2(1H)-Quinolinone Core
摘要:
Three mimetics of the peptide omega-Conotoxin MVIIA have been synthesised following the dendroid approach. The three key central amino acids of the natural peptide are mimicked by phenylguanidine (arginine), isopentyl (leucine) and aryl alcohol (tyrosine) attached to a quinolinone core at the 1- and 8-positions. The derivatives are designed to position these key groups in similar spatial orientation to that of the natural peptide in a structure that will have limited conformational flexibility. Key steps of the syntheses involve selective N-alkylation of quinolinone derivatives and guanylation of aryl amines. (C) 2000 Elsevier Science Ltd. All rights reserved.
Dendroid Peptide Structural Mimetics of ω-Conotoxin MVIIA based on a 2(1H)-Quinolinone Core
摘要:
Three mimetics of the peptide omega-Conotoxin MVIIA have been synthesised following the dendroid approach. The three key central amino acids of the natural peptide are mimicked by phenylguanidine (arginine), isopentyl (leucine) and aryl alcohol (tyrosine) attached to a quinolinone core at the 1- and 8-positions. The derivatives are designed to position these key groups in similar spatial orientation to that of the natural peptide in a structure that will have limited conformational flexibility. Key steps of the syntheses involve selective N-alkylation of quinolinone derivatives and guanylation of aryl amines. (C) 2000 Elsevier Science Ltd. All rights reserved.
[EN] PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS<br/>[FR] PROMÉDICAMENTS D'INHIBITEURS DE CETP À BASE D'OXAZOLIDINONE
申请人:MERCK SHARP & DOHME
公开号:WO2010039474A1
公开(公告)日:2010-04-08
The compounds of Formula I are prodrugs of CETP inhibitors having a central oxazolidinone ring. The compounds cyclize by the elimination of HX to form an oxazolidinone ring after administration to a patient.
The compounds of Formula I are pro-drugs of CETP inhibitors having a central oxazolidinone ring. The compounds cyclize by the elimination of HX to form an oxazolidinone ring after administration to a patient.
The compounds of Formula I are pro-drugs of CETP inhibitors having a central oxazolidinone ring. The compounds cyclize by the elimination of HX to form an oxazolidinone ring after administration to a patient.